Clinical Trials Logo
  1. Home
  2. Liver Transplantation
  3. NCT03874286

The TOGETHER Project - Liver — TOGETHER  

Liver Transplant Rejection Clinical Trial

Official title:
The Together Project-Transplant Organ Genomics to Help Prevent Rejection in Liver Transplant Recipients

Clinical Trial Summary

To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.

Clinical Trial Description

The study is a prospective, observational study utilizing peripheral blood assays that will be collected at time points that are considered standard of care at most institutions. 100 participants will be enrolled in study. Participants will have peripheral blood collected at 4 months and 12 months after liver transplant, as well as any for cause time points. Participants will also have liver biopsies collected at these time points. The results from the liver biopsies will be used in correlation with the results from the peripheral blood assays. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03874286
Study type Observational
Source Mayo Clinic
Contact
Status Completed
Phase
Start date March 15, 2017
Completion date April 30, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT01678937 - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents N/A
Completed NCT03781414 - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension Phase 2
Recruiting NCT02260375 - MSC Therapy in Liver Transplantation Phase 1
Not yet recruiting NCT04514666 - VOCs in Kidney and Liver Transplants N/A
Recruiting NCT06400771 - Safety of DNP007 in Healthy Subjects
Not yet recruiting NCT05335551 - TRU-IMMUNO: Optimizing Liver Immunosuppression
Completed NCT01745731 - Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration Phase 2
Enrolling by invitation NCT05082077 - Global Utilization And Registry Database for Improved preservAtion of doNor Livers
Completed NCT06060808 - Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
Completed NCT04789213 - Mortality, Morbidity and Risk Factors of Liver Retransplantation
Not yet recruiting NCT05655273 - Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients Phase 4
Recruiting NCT03603548 - Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial N/A
Withdrawn NCT03315052 - Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects Phase 4
Active, not recruiting NCT05325073 - Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients Phase 4
Recruiting NCT05707520 - Long-term Benefit of MPA in Liver Transplantation
Recruiting NCT04657562 - The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
Completed NCT01444079 - Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation N/A
Active, not recruiting NCT06153641 - Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients